Filing Flows › Mangoceuticals (MGRX) › Q1 2025
Mangoceuticals (MGRX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Mangoceuticals (MGRX) reported revenue of $109K for the first quarter 2025 (Q1 2025), -49% from a year earlier and +4% from the quarter before.
Mangoceuticals, Q1 2025: revenue $109K (-49% year over year), net loss $4.8M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $109K | +4% | -49% |
| Operating profit | −$4.9M | — | — |
| Net earnings | −$4.8M | — | — |
| Operating cash flow | −$2.3M | — | — |
What changed
Revenue was $109K in Q1 2025, down 49% year over year and up 4% from the previous quarter.
Gross margin was 56.8%, down 12.1 points from a year earlier. Operating costs exceeded revenue by $4.9M, an operating margin of -4440.0%. Operating expenses grew 95% against a revenue fall of 49%. The fastest-growing cost line was Other operating costs (+247%). The quarter ended with a net loss of $4.8M, wider than the previous quarter's $1.9M loss.
Operating cash flow was −$2.3M. Non-cash charges added back $277K of depreciation and amortization and $51K of share-based compensation. Working capital and other items added $2.2M.
Questions
What was Mangoceuticals' revenue in the first quarter 2025?
Mangoceuticals (MGRX) reported revenue of $109K for the first quarter 2025 (Q1 2025), -49% from a year earlier and +4% from the quarter before.
Source: Mangoceuticals 10-Q on SEC EDGAR.